Tivozanib is expected to be included as a first-line treatment recommendation for advanced renal cell carcinoma (RCC) in new proposed European guidelines.
An outline of the new proposed European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced RCC were presented at the annual ESMO 2018 Congress in Munich, Germany last week. The presentation indicated that tivozanib will be included as a first-line treatment recommendation for people with advanced clear cell RCC. Tivozanib is indicated as a treatment standard for people with good (favourable) risk or intermediate risk RCC. The guidelines are expected to be published at the end of this year.
Tivozanib was granted a license by the European Commission (EC) in August 2017 for first-line treatment of advanced RCC. Tivozanib is a potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI). Tivozanib was given marketing authorisation within the European Union (EU) based on evidence from the phase 3 TiVO-1 clinical trial, which showed superior progression free survival and an improved side effect profile compared to sorafenib, another VEGFR-TKI.
Lee Morley, Chief Executive of EUSA Pharma, the manufacturers of tivozanib, said “EUSA Pharma are pleased to receive this indication of the inclusion of tivozanib in such important European guidelines reflecting both its EU authorisation and the potential patient benefits as a result of its efficacy and tolerability profile.”